Are “Hypoallergenic” Cosmetics Really Better?
When shopping for cosmetics or skin care products, you’ll frequently see products that are labeled “hypoallergenic.” Implicit in this term is that these products are less likely to cause allergic reactions than other cosmetic products and that these products will be gentler or even safer for the skin than other products.
However, the U.S. Food and Drug Administration(FDA) counsels that consumers should realize that no federal standards or regulations exist governing the use of the term “hypoallergenic.” In other words, the decision as to whether or not a cosmetic may be labeled as “hypoallergenic” lies solely with the manufacturer. And, this term may be applied without any demonstration or proof that the product causes fewer allergic reactions than others.
When labeling of cosmetics as “hypoallergenic” first became popular, the FDA attempted to regulate use of the term. In 1975, the FDA issued a regulation governing use of the term “hypoallergenic,” stating that a cosmetic product could be labeled "hypoallergenic" only if scientific studies on human subjects showed that it caused a significantly lower rate of adverse skin reactions than similar products not making such claims. The manufacturers of cosmetics claiming to be "hypoallergenic" were to be responsible for carrying out the required tests. But this regulation was subsequently declared invalid by U.S. courts, leaving manufacturers free to apply the term as they wish.
The FDA Office of Cosmetics and Colors Fact Sheet notes that the ingredients used to make all cosmetic products are basically the same throughout the industry. Decades ago, harsh ingredients were sometimes used that indeed caused adverse reactions in some users, but these ingredients are no longer used in the cosmetic manufacturing process. Scientific studies demonstrating that certain products or classes of products cause fewer adverse reactions than others on the basis of “hypoallergenicity” are lacking.
The bottom line is that the term “hypoallergenic” has very little meaning and is primarily used as a marketing tool. It’s important to understand that it is impossible to guarantee that a cosmetic or skin care product will never produce an allergic reaction. Since the FDA does require that cosmetic ingredients be listed on product labels, consumers who have had allergic reactions or problems with a specific substance can avoid purchasing products that contain these substances.
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.


